IndustryCompany release
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
Windward Bio Group AG · Thu 12 Nov 2026
Swiss clinical-stage biotech Windward Bio Group AG, which is developing ultra-long-acting antibodies for respiratory and dermatologic diseases, priced its initial public offering on Nov. 12, 2026. It is selling 10,294,117 common shares at $17.00 each and has granted underwriters a 30-day option for up to 1,544,117 more. Expected gross proceeds of $225.0 million include a concurrent private placement and exclude the underwriters' option.
Company's press release: Windward Bio Group AG ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IM Cannabis Corp. (IMCC) · Fri 13 Nov 2026
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
Helus Pharma Inc. (HELP) · Fri 13 Nov 2026
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IM Cannabis Corp. (IMCC) · Fri 13 Nov 2026
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
🇺🇸 DataMeds AI, Inc. (MEDS) · Fri 13 Nov 2026
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
🇺🇸 Xenetic Biosciences, Inc. (XBIO) · Fri 13 Nov 2026
IndustryCompany releaseLifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partners
🇺🇸 Lifeward Ltd. (LFWD) · Fri 13 Nov 2026